Eva.Veghelyi_90 Apr 06

Webinar: Which in-process bioanalytics do we really need for cell-based therapy manufacture?

In addition to our upcoming Phacilitate SIG Automation event (30-31 May 2017, Edinburgh), we ran a webinar that looked into how to fill the current innovation gap around bioanalytics for cell-based therapy production as well as where and how to bring these tools in-process.

Topic: Which in-process bioanalytics do we really need for cell-based therapy manufacture?

We explored the shifting paradigm of quality in cell-based therapy manufacturing, with a particular focus on the core concept of embedding quality control in the process:

  • What does ‘quality’ mean in cell therapy, fundamentally?
  • Case studies on evolving autologous and allogeneic cell therapy QC approaches
  • How is in-process monitoring being embedded at the cutting edge today?

Speakers:

  • Dr Stephen Ward, Chief Operating Officer, Cell and Gene Therapy Catapult (moderator)
  • Dr Damian Marshall, Head of Analytical Development, Cell and Gene Therapy Catapult
  • Dr Sarah Snykers, QC Manager, Celyad
  • Dr John Elliott, Cell Systems Science Group, NIST

Agenda:
Introduction
Short presentations & case studies
Panel discussion
Audience Q&A

You can access this webinar by simply clicking HERE.